在A549/DDP细胞中,LncRNA PCIF1通过竞争性结合miR-326来促进有氧糖解,以调节PKM表达
Wan Zhong1, Chun Wang2, Ye Sun3
1Department of Obstetrics and Gynecology, General Hospital of the Northern Theater Command, 83 Wenhua Road, Shenhe District, Shenyang, 110016, China.
Molecular and cellular probes
|July 29, 2024
概括
在非小细胞肺癌 (NSCLC) 中,lncRNA PCIF1 通过增强糖解促进了对西斯的耐药性. 针对LncRNA PCIF1提供了对抗西斯胺抗性NSCLC的潜在治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症基因组学 癌症基因组学
背景情况:
- 在非小细胞肺癌 (NSCLC) 治疗中,西斯普拉丁耐药性是一个主要的挑战.
- 了解基底的分子机制,西斯普拉丁耐药性对于开发有效的疗法至关重要.
研究的目的:
- 通过转录组分析,研究NSCLC中西斯普拉丁耐药性的分子机制.
- 确定潜在的治疗点,以克服NSCLC中西斯普拉丁耐药性.
主要方法:
- 在A549和耐思白A549/DDP细胞上进行了RNA测序.
- 进行了基因丰富分析 (GO,KEGG) 和竞争性内源RNA (ceRNA) 网络的构建.
- 在体外和体内实验验验证了已识别的途径在西斯普拉丁耐药性中的作用.
主要成果:
- 耐西斯普拉丁的A549/DDP细胞呈现高糖解和增加糖解相关基因的表达,特别是PKM.
- LncRNA PCIF1被确定为A549/DDP细胞中的新型标记物,并充当分子海绵.
- LncRNA PCIF1针对miR-326进行PKM上调,促进糖解和西斯抗性.
结论:
- 在NSCLC中,LncRNA PCIF1通过调节PKM并增强糖分解来促进对的耐药性.
- LncRNA PCIF1 作为一种潜在的生物标志物和治疗抗西斯普拉丁NSCLC的治疗标.
相关概念视频
PI3K/mTOR/AKT Signaling Pathway
3.5K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.5K
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
MicroRNAs
3.0K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.0K
piRNA - Piwi-interacting RNAs
6.8K
PIWI-interacting RNAs, or piRNAs, are the most abundant short non-coding RNAs. More than 20,000 genes have been found in humans that code for piRNAs while only 2000 genes have been found for miRNAs. piRNAs can act at the transcriptional and post-transcriptional levels and have a vital role in silencing transposable elements present in germ cells. They are also involved in epigenetic silencing and activation. Previously, they were thought to function only in germ cells but new evidence suggests...
6.8K
lncRNA - Long Non-coding RNAs
8.5K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.5K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K


